In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug. Alzheimer's Disease, Aduhelm (Drug), Labeling and Labels (Product), Drugs (Pharmaceuticals), Clinical Trials, Food and Drug Administration, Biogen Inc, Health Insurance and Managed Care